Denied

No. 21-1567

Biogen International GmbH, et al. v. Mylan Pharmaceuticals Inc.

from the United States Court of Appeals for the Federal Circuit

See other cases from the Federal Circuit.

Docket Entries

Petition DENIED.

DISTRIBUTED for Conference of 9/28/2022.

Reply of petitioners Biogen International GmbH and Biogen MA Inc. filed. (Distributed)

Brief of respondent Mylan Pharmaceuticals Inc. in opposition filed.

Brief amici curiae of Pharmaceutical Research and Manufacturers of America, et al.

Brief amicus curiae of New England Legal Foundation filed.

Brief amicus curiae of Chemistry and the Law Division of the American Chemical Society filed.

Motion to extend the time to file a response is granted and the time is extended to and including August 15, 2022.

Motion to extend the time to file a response from July 15, 2022 to August 15, 2022, submitted to The Clerk.

Petition for a writ of certiorari filed. (Response due July 15, 2022)

Parties

Biogen International GmbH and Biogen MA Inc., Petitioner, represented by Seth P. Waxman

Mylan Pharmaceuticals Inc., Respondent, represented by Nathan Kip Kelley

Amici Curiae

Chemistry and the Law Division of the American Chemical Society, Amicus Curiae, represented by James Clark Carver

New England Legal Foundation, Amicus Curiae, represented by Daniel Bradford Winslow

Pharmaceutical Research and Manufacturers of America; Biotechnology Innovation Organization, Amicus Curiae, represented by Jeffrey P. Kushan

 
Last updated: November 21, 2024